Travere Therapeutics, Inc.

TVTX

Travere Therapeutics, Inc.

TVTX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-12Shares Purchased (TTM):0Shares Sold (TTM):837,747

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:99,427,920Shares Outstanding:91,868,862Institutional Ownership Pct.:108.23%

Earnings Market Reaction:

Filing Date:2026-08-04Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	118	78	93	111	75	62	59	36	32	43	58	144
Available For Sale Securities Debt Securities	371	186	230	144	244	260	312	241	293	398	509	490
Accounts Receivable Net Current	81	87	80	83	39	34	27	25	24	23	21	15
Inventory Gross	8	6	6	6	4	4	6	6	6	5	-	-
Inventory Net	-	-	36	-	-	-	42	-	-	-	9	21
Prepaid Expense And Other Assets Current	37	34	29	28	17	14	13	16	13	13	19	16
Assets Current	615	393	438	371	380	374	417	325	369	481	617	686
Assets Of Disposal Group Including Discontinued Op…	-	-	-	-	-	-	-	-	-	-	0	0
Inventory Noncurrent	32	31	30	32	34	34	36	37	37	38	31	-
Property Plant And Equipment Net	3	4	4	4	5	5	5	6	7	7	7	8
Operating Lease Right Of Use Asset	9	10	11	11	12	13	14	16	16	17	18	19
Intangible Assets Net Excluding Goodwill	132	110	114	109	106	104	104	104	105	101	104	107
Other Assets Noncurrent	9	8	9	10	20	19	18	17	17	19	11	13
Assets	799	555	605	539	555	549	594	504	551	664	789	833
Liabilities And Stockhold…
Disposal Group Including Discontinued Operation As…	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities Current
Accounts Payable Current	7	13	25	18	19	15	24	23	26	17	42	25
Accrued Liabilities Current	136	104	126	106	82	77	86	84	80	140	119	96
Convertible Debt Current	-	-	0	0	69	69	69	69	-	-	0	-
Operating Lease Liability Current	6	6	6	6	6	5	5	5	5	5	5	5
Contract With Customer Liability Current	-	-	-	-	-	-	3	4	5	6	7	9
Other Liabilities Current	2	2	3	5	14	16	17	5	5	5	5	5
Liabilities Current	152	125	160	135	190	182	201	190	121	173	178	139
Convertible Debt Noncurrent	-	-	312	311	311	311	310	310	378	378	377	377
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	-	-	-	-	-	-	0	0
Contract With Customer Liability Noncurrent	-	-	-	-	-	-	-	-	0	1	2	5
Convertible Debt	603	312	-	-	-	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	8	10	11	13	14	16	17	19	20	21	23	24
Other Liabilities Noncurrent	12	9	8	6	8	7	7	16	17	16	10	8
Liabilities	775	456	490	465	523	516	535	535	536	589	588	553
Stockholders Equity
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	-	-	-	-	-	-	0	0
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,570	1,610	1,589	1,550	1,535	1,522	1,506	1,357	1,349	1,338	1,328	1,319
Retained Earnings Accumulated Deficit	-1,545	-1,510	-1,473	-1,475	-1,501	-1,488	-1,447	-1,387	-1,332	-1,262	-1,126	-1,035
Accumulated Other Comprehensive Income Loss Net Of…	-1	-1	-1	-1	-1	-1	-0	-1	-2	-2	-1	-4
Stockholders Equity	25	99	115	74	33	33	59	-30	15	74	201	280
Liabilities And Stockholders Equity	799	555	605	539	555	549	594	504	551	664	789	833
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	20	20	20	20	20	20	20	20	20	20	20	20
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	94	92	91	89	89	89	87	78	76	76	75	75
Shares Outstanding	94	92	91	89	89	89	87	78	76	76	75	75

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	5.05%	31.04%	27.72%	-	-	-	-	-	-	-	-	-
2025	-23.70%	-31.07%	-22.40%	1.51%	46.75%	62.76%	17.00%	16.39%	-6.00%	-5.12%	-1.16%	45.39%
2024	13.28%	25.50%	50.99%	-2.81%	64.61%	93.40%	4.29%	-1.83%	4.97%	-10.24%	-34.03%	-8.92%
2023	-	-	-	-	-	-	-10.58%	25.21%	19.78%	-9.54%	-23.07%	-23.91%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.05	3.13	2.74	2.75	2.00	2.05	2.08	1.71	3.04	2.78	3.47	4.92
Quick Ratio	3.75	2.81	2.33	2.50	1.89	1.95	1.80	1.59	2.89	2.68	3.31	4.66
Working Capital	463.12M	267.24M	277.66M	236.04M	190.03M	191.71M	215.95M	134.70M	247.71M	307.85M	438.87M	546.80M
Leverage & Debt
Debt to Equity	31.60	4.62	4.27	6.32	15.96	15.72	9.06	-17.56	35.38	7.96	2.93	1.98
Interest Coverage TTM	-4.27	-5.60	-5.85	-8.09	-15.24	-20.22	-28.96	-25.46	-27.97	-30.42	-27.36	-35.63
Debt Ratio	0.97	0.82	0.81	0.86	0.94	0.94	0.90	1.06	0.97	0.89	0.75	0.66
Efficiency & Turnover
Asset Turnover TTM	0.87	0.97	0.82	0.84	0.60	0.45	0.34	0.30	0.28	0.21	0.20	0.10
Days Sales Outstanding TTM	36.84	41.42	39.89	45.29	34.54	38.10	37.80	35.65	46.09	51.88	47.53	63.00
Receivables Turnover TTM	9.91	8.81	9.15	8.06	10.57	9.58	9.66	10.24	7.92	7.04	7.68	5.79
Per Share Metrics
Diluted EPS TTM	-0.46	-0.23	-0.29	-0.86	-1.90	-2.57	-4.08	-4.52	-1.88	-2.09	-1.50	-1.14
Free Cash Flow Per Share TTM	0.32	-0.02	0.07	-0.90	-1.63	-2.15	-3.32	-3.69	-3.81	-4.21	-3.78	-3.47
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	98.60%	98.58%	97.89%	97.63%	96.89%	96.01%	96.68%	95.21%	94.70%	94.34%	92.12%	92.39%
Operating Profit Margin TTM	-6.84%	-10.64%	-12.80%	-20.91%	-51.58%	-83.08%	-138.88%	-175.63%	-221.66%	-276.13%	-267.24%	-506.31%
Net Profit Margin TTM	-7.35%	-4.00%	-5.21%	-20.32%	-50.64%	-82.88%	-137.90%	-172.75%	-82.14%	-103.47%	-76.70%	-110.31%
Growth Metrics
Net Revenue Growth (1Y)	77.12%	96.03%	110.45%	114.22%	87.94%	75.65%	60.55%	157.82%	154.18%	69.52%	32.69%	-58.02%
Net Income Growth (1Y)	-74.29%	-90.55%	-92.06%	-74.81%	15.86%	40.70%	188.64%	303.74%	-52.54%	-44.22%	-60.00%	-67.06%
EPS Growth (1Y)	-75.54%	-90.91%	-92.97%	-78.04%	0.96%	22.83%	171.73%	296.09%	-53.46%	-50.70%	-65.66%	-72.35%
Valuation Metrics
P/E TTM	-122.18	-127.41	-133.44	-24.09	-7.79	-6.98	-4.27	-3.10	-4.37	-3.69	-5.99	-7.84
P/B TTM	216.56	27.65	29.69	28.99	40.20	48.24	23.26	-35.73	42.06	8.03	3.32	2.44
P/S TTM	8.98	5.09	6.95	4.89	3.94	5.79	5.89	5.35	3.59	3.82	4.60	8.64
Market Cap	5.31B	2.73B	3.41B	2.13B	1.32B	1.58B	1.37B	1.09B	637.05M	594.72M	667.66M	682.17M
Enterprise Value	5.80B	2.96B	3.63B	2.33B	1.62B	1.90B	1.69B	1.43B	982.89M	929.16M	986.75M	914.76M
Calculated Values
Free Cash Flow TTM	30.07M	-2.18M	6.39M	-80.42M	-145.29M	-190.37M	-261.86M	-286.99M	-295.44M	-324.41M	-280.69M	-264.86M
Net Debt	485.05M	233.72M	218.69M	200.44M	304.70M	317.52M	320.45M	342.15M	345.83M	334.44M	319.09M	232.59M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-12Sale

Owner: Baynes, Roy D.

Title: -

Shares: 4,500

Price/Share: $50.00

Value: $225,000.00

Shares Owned: 41,500

Relationship: Director

Ownership: Direct

2026-06-12Sale

Owner: Coughlin, Timothy

Title: -

Shares: 10,000

Price/Share: $50.07

Value: $500,700.00

Shares Owned: 56,250

Relationship: Director

Ownership: Direct

2026-05-15Sale

Owner: Coughlin, Timothy

Title: -

Shares: 3,250

Price/Share: $43.49

Value: $141,342.50

Shares Owned: 52,250

Relationship: Director

Ownership: Direct

2026-05-06Sale

Owner: Inrig, Jula

Title: CHIEF MEDICAL OFFICER

Shares: 311

Price/Share: $43.95

Value: $13,668.45

Shares Owned: 113,238

Relationship: Officer

Ownership: Direct

2026-05-06Sale

Owner: Reed, Elizabeth E

Title: Chief Legal Officer and GC

Shares: 2,076

Price/Share: $43.95

Value: $91,240.20

Shares Owned: 105,211

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-12	Baynes, Roy D.	Director	-	Direct	Sale	4,500	50.00	$225,000.00	41,500	4
2026-06-12	Coughlin, Timothy	Director	-	Direct	Sale	10,000	50.07	$500,700.00	56,250	4
2026-05-15	Coughlin, Timothy	Director	-	Direct	Sale	3,250	43.49	$141,342.50	52,250	4
2026-05-06	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	311	43.95	$13,668.45	113,238	4
2026-05-06	Reed, Elizabeth E	Officer	Chief Legal Officer and GC	Direct	Sale	2,076	43.95	$91,240.20	105,211	4
2026-05-06	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	22,500	43.95	$988,875.00	432,886	4
2026-05-06	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	310	43.95	$13,624.50	118,658	4
2026-05-06	Rote, William E.	Officer	Chief Research Officer	Direct	Sale	2,763	43.95	$121,433.85	115,474	4
2026-05-05	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	2,174	46.65	$101,417.10	140,684	4
2026-05-05	Baynes, Roy D.	Director	-	Direct	Sale	4,500	46.65	$209,925.00	37,500	4
2026-05-04	Meckler, Jeffrey A	Director	-	Direct	Sale	8,000	45.00	$360,000.00	87,500	4
2026-05-01	Baynes, Roy D.	Director	-	Direct	Sale	9,750	44.22	$431,145.00	37,500	4
2026-04-22	Rote, William E.	Officer	Chief Research Officer	Direct	Sale	9,100	39.09	$355,719.00	113,987	4
2026-04-15	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,018	42.61	$43,376.98	111,473	4
2026-04-15	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,014	42.61	$43,206.54	116,899	4
2026-04-15	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	64,000	41.81	$2,675,840.00	432,886	4
2026-04-15	Reed, Elizabeth E	Officer	Chief Legal Officer and GC	Direct	Sale	6,785	42.08	$285,512.80	105,211	4
2026-04-14	Lyons, Gary A	Director	-	Direct	Sale	8,000	41.07	$328,560.00	57,500	4
2026-04-14	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	7,215	41.93	$302,524.95	138,608	4
2026-04-14	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	21,977	41.07	$902,595.39	42,353	4
2026-04-14	Baynes, Roy D.	Director	-	Direct	Sale	32,750	41.60	$1,362,400.00	37,500	4
2026-04-06	Baynes, Roy D.	Director	-	Direct	Sale	10,000	33.00	$330,000.00	37,500	4
2026-04-01	Reed, Elizabeth E	Officer	Chief Legal Officer and GC	Direct	Sale	10,000	30.00	$300,000.00	105,211	4
2026-04-01	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	60,000	31.01	$1,860,600.00	432,886	4
2026-03-16	Reed, Elizabeth E	Officer	Chief Legal Officer and GC	Direct	Sale	10,000	28.09	$280,900.00	105,211	4
2026-02-20	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	60,000	30.10	$1,806,000.00	432,886	4
2026-02-17	Reed, Elizabeth E	Officer	Chief Legal Officer and GC	Direct	Sale	10,000	27.88	$278,800.00	105,211	4
2026-02-04	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,779	32.48	$57,781.92	105,706	4
2026-02-04	Reed, Elizabeth E	Officer	Chief Legal Officer and GC	Direct	Sale	2,994	32.40	$97,005.60	105,211	4
2026-02-04	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,745	32.52	$56,747.40	111,226	4
2026-02-03	Reed, Elizabeth E	Officer	Chief Legal Officer and GC	Direct	Sale	7,175	32.12	$230,461.00	108,205	4
2026-02-03	Rote, William E.	Officer	Chief Research Officer	Direct	Sale	12,446	32.87	$409,100.02	109,087	4
2026-02-03	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	4,333	32.12	$139,175.96	49,080	4
2026-02-03	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	7,310	32.12	$234,797.20	131,823	4
2026-02-03	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	7,242	32.12	$232,613.04	112,971	4
2026-02-03	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	100,087	32.38	$3,240,817.06	432,886	4
2026-02-03	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	6,956	32.12	$223,426.72	107,485	4
2026-01-27	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	51,865	30.10	$1,561,136.50	419,173	4
2026-01-20	Reed, Elizabeth E	Officer	Chief Legal Officer and GC	Direct	Sale	10,000	27.34	$273,400.00	90,270	4
2026-01-06	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	445	37.75	$16,798.75	86,311	4
2025-12-24	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	4,980	40.00	$199,200.00	113,013	4
2025-12-24	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	15,000	42.00	$630,000.00	88,787	4
2025-12-24	Rote, William E.	Officer	Chief Research Officer	Direct	Sale	60,000	40.10	$2,406,000.00	101,443	4
2025-12-24	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	7,402	40.00	$296,080.00	38,233	4
2025-12-15	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	2,910	36.00	$104,760.00	45,635	4
2025-12-01	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	20,000	35.01	$700,200.00	92,083	4
2025-11-04	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	67,115	36.00	$2,416,140.00	48,545	4
2025-10-31	Coughlin, Timothy	Director	-	Direct	Sale	18,000	35.03	$630,540.00	55,500	4
2025-10-31	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	5,591	35.00	$195,685.00	119,071	4
2025-10-29	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	27,128	30.12	$817,095.36	419,173	4
2025-10-28	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	2,662	30.00	$79,860.00	124,662	4
2025-09-22	Reed, Elizabeth E	Officer	Chief Legal Officer and GC	Direct	Sale	10,000	25.00	$250,000.00	89,878	4
2025-09-04	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	119	19.71	$2,345.49	92,083	4
2025-08-27	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	470	17.31	$8,135.70	92,656	4
2025-07-01	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	815	14.65	$11,939.75	88,787	4
2025-05-05	Rote, William E.	Officer	Chief Research Officer	Direct	Sale	3,198	21.05	$67,317.90	100,241	4
2025-05-05	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,784	21.05	$37,553.20	93,126	4
2025-05-05	Reed, Elizabeth E	Officer	Chief Legal Officer and GC	Direct	Sale	4,920	21.05	$103,566.00	89,482	4
2025-05-05	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	1,771	21.05	$37,279.55	128,215	4
2025-05-05	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	18,924	21.05	$398,350.20	419,173	4
2025-04-11	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	48	13.14	$630.72	89,990	4
2025-02-12	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,568	23.53	$60,425.04	89,602	4
2025-02-12	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	2,568	23.53	$60,425.04	125,066	4
2025-02-12	Reed, Elizabeth E	Officer	SVP, GC & CORPORATE SECRETARY	Direct	Sale	8,000	23.53	$188,240.00	89,482	4
2025-02-12	Rote, William E.	Officer	SENIOR VICE PRESIDENT, R&D	Direct	Sale	5,200	23.53	$122,356.00	98,519	4
2025-02-11	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	54,244	25.00	$1,356,100.00	54,410	4
2025-02-11	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	11,375	24.04	$273,455.00	419,173	4
2025-02-06	Baynes, Roy D.	Director	-	Direct	Sale	10,000	22.00	$220,000.00	31,000	4
2025-02-04	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,066	20.11	$21,437.26	84,170	4
2025-02-03	Reed, Elizabeth E	Officer	SVP, GC & CORPORATE SECRETARY	Direct	Sale	8,951	19.78	$177,050.78	89,482	4
2025-02-03	Rote, William E.	Officer	SENIOR VICE PRESIDENT, R&D	Direct	Sale	8,951	19.78	$177,050.78	95,719	4
2025-02-03	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	5,192	20.12	$104,463.04	90,038	4
2025-02-03	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	3,348	20.12	$67,361.76	63,654	4
2025-02-03	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	5,166	20.12	$103,939.92	122,708	4
2025-02-03	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	50,691	20.21	$1,024,465.11	430,548	4
2025-01-23	Baynes, Roy D.	Director	-	Direct	Sale	16,000	20.00	$320,000.00	31,000	4
2025-01-22	Rote, William E.	Officer	SENIOR VICE PRESIDENT, R&D	Direct	Sale	2,437	19.46	$47,424.02	83,170	4
2025-01-22	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,736	19.46	$208,922.56	351,239	4
2025-01-22	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	1,584	18.94	$30,000.96	106,374	4
2025-01-22	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	925	18.94	$17,519.50	54,002	4
2025-01-22	Reed, Elizabeth E	Officer	SVP, GC & CORPORATE SECRETARY	Direct	Sale	2,437	19.46	$47,424.02	76,933	4
2025-01-22	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	865	18.94	$16,383.10	73,730	4
2025-01-06	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	440	18.76	$8,254.40	59,443	4
2024-12-26	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	15,000	17.22	$258,300.00	54,927	4
2024-11-25	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	12,090	18.30	$221,247.00	54,927	4
2024-10-04	Lyons, Gary A	Director	-	Direct	Sale	40,000	14.75	$590,000.00	51,000	4
2024-09-30	Meckler, Jeffrey A	Director	-	Direct	Sale	40,000	14.06	$562,400.00	81,000	4
2024-09-10	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	684	12.98	$8,878.32	61,949	4
2024-09-09	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	2,191	11.52	$25,240.32	107,958	4
2024-09-09	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	21,125	11.52	$243,360.00	361,975	4
2024-09-09	Rote, William E.	Officer	SENIOR VICE PRESIDENT, R&D	Direct	Sale	4,387	11.52	$50,538.24	84,455	4
2024-09-09	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	2,490	11.52	$28,684.80	74,595	4
2024-09-09	Reed, Elizabeth E	Officer	SVP, GC & CORPORATE SECRETARY	Direct	Sale	4,387	11.52	$50,538.24	78,633	4
2024-09-09	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,191	11.52	$25,240.32	62,633	4
2024-09-04	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	514	9.51	$4,888.14	70,335	4
2024-04-11	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	54	6.74	$363.96	70,849	4
2024-02-01	Rote, William E.	Officer	SENIOR VICE PRESIDENT, R&D	Direct	Sale	4,764	8.70	$41,446.80	80,720	4
2024-02-01	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	2,820	8.53	$24,054.60	52,017	4
2024-02-01	Reed, Elizabeth E	Officer	SVP, GC & CORPORATE SECRETARY	Direct	Sale	4,764	8.70	$41,446.80	76,270	4
2024-02-01	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,818	8.53	$32,567.54	70,903	4
2024-02-01	Inrig, Jula	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,174	8.53	$18,544.22	58,074	4
2024-02-01	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	4,195	8.53	$35,783.35	99,503	4
2024-02-01	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	19,122	8.70	$166,361.40	350,600	4
2024-01-23	Dube, Eric M	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,873	8.96	$70,542.08	234,722	4
2024-01-23	Reed, Elizabeth E	Officer	SVP, GC & CORPORATE SECRETARY	Direct	Sale	2,062	8.96	$18,475.52	56,034	4
2024-01-23	Cline, Christopher R.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	853	9.07	$7,736.71	49,721	4
2024-01-23	Heerma, Peter	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	1,559	9.07	$14,140.13	78,698	4
2024-01-23	Rote, William E.	Officer	SENIOR VICE PRESIDENT, R&D	Direct	Sale	2,062	8.96	$18,475.52	60,484	4
2024-01-23	Calvin, Sandra	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	910	9.07	$8,253.70	41,337	4
2024-01-04	Inrig, Jula	Officer	Chief Medical Officer	Direct	Sale	440	9.17	$4,034.80	35,248	4
2023-10-03	Heerma, Peter	Officer	Chief Commercial Officer	Direct	Sale	3,091	8.25	$25,500.75	80,257	4
2023-09-05	Cline, Christopher R.	Officer	Chief Financial Officer	Direct	Sale	457	14.71	$6,722.47	50,574	4
2023-09-05	Rote, William E.	Officer	Senior Vice President, R&D	Direct	Sale	1,815	14.71	$26,698.65	61,173	4
2023-09-05	Dube, Eric M	Director,Officer	Chief Executive Officer	Direct	Sale	4,455	14.71	$65,533.05	242,595	4
2023-09-05	Reed, Elizabeth E	Officer	SVP, GC & Corporate Secretary	Direct	Sale	1,815	14.71	$26,698.65	58,096	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

108.23%

Inst. Shares: 99,427,920

Shares Outstanding: 91,868,862

2025-12-31

113.21%

Inst. Shares: 100,998,591

Shares Outstanding: 89,211,813

2025-09-30

111.86%

Inst. Shares: 99,811,577

Shares Outstanding: 89,230,420

2025-06-30

110.87%

Inst. Shares: 98,616,735

Shares Outstanding: 88,945,624

2025-03-31

107.80%

Inst. Shares: 95,251,466

Shares Outstanding: 88,355,973

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	99,427,920	91,868,862	108.23%
2025-12-31	100,998,591	89,211,813	113.21%
2025-09-30	99,811,577	89,230,420	111.86%
2025-06-30	98,616,735	88,945,624	110.87%
2025-03-31	95,251,466	88,355,973	107.80%
2024-12-31	94,005,784	78,888,861	119.16%
2024-09-30	81,112,712	77,779,379	104.29%
2024-06-30	86,549,000	77,500,245	111.68%
2024-03-31	83,779,714	77,136,493	108.61%
2023-12-31	81,118,078	74,267,418	109.22%
2023-09-30	79,017,680	76,305,603	103.55%
2023-06-30	79,593,465	76,001,801	104.73%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Travere Therapeutics, Inc. (TVTX) — SEC Financial Statements & Analysis

Travere Therapeutics, Inc. (TVTX) is a pharmaceutical preparations company, incorporated in CA. Travere Therapeutics, Inc. trades on Nasdaq as: TVTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Travere Therapeutics, Inc. reported a 77.12% year-over-year revenue growth, a Gross Profit Margin of 98.60% (TTM), a Debt-to-Equity ratio of 31.60x, a Price-to-Sales (P/S) ratio of 8.98x (TTM), a Price-to-Book (P/B) ratio of 216.56x (TTM), at a market cap of $5.31B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 77.12%
Gross Profit Margin TTM: 98.60%
Debt To Equity: 31.60x
P/S TTM: 8.98x
P/B TTM: 216.56x
Market Cap: $5.31B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Travere Therapeutics, Inc. in?

Travere Therapeutics, Inc. (TVTX) operates in the Pharmaceutical Preparations industry.

What is TVTX's market cap?

Travere Therapeutics, Inc. (TVTX) has a market capitalization of $5.31B as of 2026-06-30.

What exchange does TVTX trade on?

Travere Therapeutics, Inc. (TVTX) trades on the Nasdaq.

Where is Travere Therapeutics, Inc. incorporated?

Travere Therapeutics, Inc. is incorporated in CA.